Robyn Faleafine, MBAHM’s Post

Join CURE, City of Hope, & Susan G. Komen on July 18 at 5:30 PM in Irvine, CA for Educated Patient Updates in Metastatic Breast Cancer. Hear from breast cancer experts and connect with fellow nurses, patients, survivors, and caregivers. Knowledge you'll walk away with includes: - Understanding metastatic breast cancer and its subtypes - Initial hormone therapy for treatment of ER+/HER2- metastatic breast cancer - Biomarkers: What they are and why we test for them - Next hormone therapy for ER+/HER2- metastatic breast cancer that progresses or stops responding - A hypothetical example of a patient’s treatment strategy Reserve your seat today: https://ow.ly/pahm50SrT06

What is the future for breast cancer diagnostics?  🎥  In this short film we look at the evolving landscape, and  the increasing significance of diagnostics in our targeted approach to cancer treatment. As Professor John Bartlett puts it, 'Diagnostics are becoming much, much more important now as we start to target drugs against specific changes in cancer. Now we're getting to the actual tailoring of therapy.' Discover how MammaTyper® is revolutionizing patient identification for targeted drug therapy, offering not only cost savings but also life-saving benefits and advancements in cancer care. We want to pave the way for personalized medicine in the fight against breast cancer.  #BreastCancerAwareness #FutureOfMedicine #PersonalizedCare"

The SunRISe-1 phase 2 trial is making waves! Learn about the innovative combination of intravesical TAR-200 and systemic cetrelimab in treating high-risk nonmuscle-invasive bladder cancer. Neal Shore, MD, FACS, explains the trial design, key efficacy, and safety endpoints. Don't miss this critical update on bladder cancer treatment. Watch the full discussion here: https://bit.ly/45gYC24

With prostate cancer being the second most common cancer in men and fourth most common overall, this #ProstateCancerAwarenessMonth we are highlighting the theme of "putting pressure on prostate cancer." Underscoring the need for relentless efforts in awareness, screening, and treatment is important not just for this month, but throughout the entire year. By increasing public knowledge about prostate cancer, promoting regular screenings, and utilizing advanced diagnostic tools, we can exert the necessary pressure to reduce the impact of this disease. Read our “Putting Pressure on Prostate Cancer” blog to learn how you can receive and achieve healthcare that empowers this Prostate Cancer Awareness Month: https://lnkd.in/d5Vgu3Bc #GEHealthCare #HealthcareThatEmpowers #Prostate

With prostate cancer being the second most common cancer in men and fourth most common overall, this #ProstateCancerAwarenessMonth we are highlighting the theme of "putting pressure on prostate cancer." Underscoring the need for relentless efforts in awareness, screening, and treatment is important not just for this month, but throughout the entire year. By increasing public knowledge about prostate cancer, promoting regular screenings, and utilizing advanced diagnostic tools, we can exert the necessary pressure to reduce the impact of this disease. Read our “Putting Pressure on Prostate Cancer” blog to learn how you can receive and achieve healthcare that empowers this Prostate Cancer Awareness Month: https://lnkd.in/gdusd-Xg #GEHealthCare #HealthcareThatEmpowers #Prostate

So, how prevalent is ecDNA in cancer? ecDNA are present in about 14% of cancer at diagnosis and up to 32% of advanced cancers, across multiple tumor types. That is one reason why Boundless is working tirelessly to bring transformative new medicines to patients with oncogene amplified cancer through ecDNA-directed therapies (ecDTx), making treatment more effective and offering new possibilities for patients to overcome this challenging disease. Learn more about the prevalence of ecDNA below. 

When estrogen receptors are overexpressed, they can lead to tumor growth in breast cancer. This can be seen in estrogen receptor-positive and human epidermal receptor 2-negative (ER+/HER2-) breast cancer. Treatment plans for this type of breast cancer could benefit from state-of-the-art adjuvant therapies that may potentially help prevent recurrence. Learn more about how Lilly is approaching adjuvant therapies for breast cancer at https://e.lilly/49tmgtH. #MyStyleMatters #BlackHealthMatters #BreastCancerSurvivor #ClinicalTrials #BreastCancer #BreastCancerAwareness #CancerSupport #BreastCancerJourney #LifeAfterCancer #BlackWomenWithBreastCancer #CancerAwareness #BreastCancerWarrior #CancerFighter #PinkRibbon #SaveASister #BreastCancerResearch #IWishIKnew

Efficacy of Oral SERDs in Patients With ER+/HER2− Metastatic Breast Cancer Stratified by ESR1 Wild-Type and Mutant Subgroups Annals of Oncology TAKE-HOME MESSAGE This pooled analysis of data from randomized trials showed progression-free survival benefits of treatment with oral SERDs in patients with advanced ER+/HER2− metastatic breast cancer, largely driven by patients with ESR1-mutant tumors. Subgroup analyses also suggested that a prior response to CDK4/6 inhibitor therapy may predict improved progression-free survival with oral SERD therapy. These findings are in line with the recent FDA approval of elacestrant for patients with ESR1-mutant breast cancer.

Honored to work on this first-of-its kind feature for Everyday Health on anti-body drug conjugates, a new form of treatment for HR-positive/HER2-negative metastatic breast cancer. These drugs can extend survival and minimize side effects for patients who have already gone through other treatments --- and in the future, they may be a first-line therapy. #cancertreatment #medicaladvancements #breastcancer

On #RareCancerDay, September 30, join Kura Oncology in showing support for patients, clinicians, and scientists fighting rare cancers. Despite >500 types of rare cancers, fewer than 40,000 people are affected annually. With fewer patients, rare cancers can be hard to study, treat, and cure. Through its ongoing clinical trial programs, Kura Oncology is exploring new therapies designed to address rare cancer challenges. Learn about our clinical trial programs in head and neck cancer, lung cancer, and acute leukemias: https://bit.ly/4earkWd